| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2006-05-18 08:38:06 UTC |
|---|
| Update Date | 2021-09-14 15:40:11 UTC |
|---|
| HMDB ID | HMDB0001926 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | 17a-Ethynylestradiol |
|---|
| Description | Ethinyl estradiol. A semisynthetic alkylated estradiol with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in oral contraceptives. -- Pubchem; estradiol (17-beta estradiol) (also oestradiol) is a sex hormone. Labelled the "female" hormone but also present in males it represents the major estrogen in humans. Critical for sexual functioning, estradiol also supports bone growth. -- Wikipedia ; One of the fascinating twists to mammalian sexual differentiation is that estradiol is one of the two active metabolites of testosterone in males (the other being dihydrotestosterone). estradiol cannot be transferred readily from the circulation into the brain. Since fetuses of both sexes are exposed to similarly high levels of maternal estradiol, it can play little role in prenatal sexual differentiation. However, testosterone enters the central nervous system more freely and significant amounts are aromatized to estradiol within the brain of most male mammals, including humans. There is now much evidence that the programming of adult male sexual behavior in "lower mammals," (such as mounting rather than lordosis behavior), is largely dependent on estradiol produced in the central nervous system during prenatal life and early infancy from testosterone. We do not yet know whether this process plays a minimal or significant part in human sexual behaviors. -- Wikipedia ; A synthetic form of estradiol, called ethinyl estradiol is a major component of hormonal contraceptive devices. Combined oral contraceptives contain ethinyl estradiol and a progestin, which both contribute to the inhibition of GnRH, LH, and FSH. The inhibition of these hormones accounts for the ability of combined oral contraceptives or birth control pills to prevent ovulation and thus prevent pregnancy. Other types of hormonal birth control contain only progestins and no ethinyl estradiol. -- Wikipedia . |
|---|
| Structure | [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3 InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 17-Ethinyl-3,17-estradiol | ChEBI | | 17-Ethinyl-3,17-oestradiol | ChEBI | | 17-Ethinylestradiol | ChEBI | | 17alpha-Ethinyl estradiol | ChEBI | | Ethinyl estradiol | ChEBI | | Ethinylestradiol | ChEBI | | Ethinyloestradiol | ChEBI | | Ethynyl estradiol | ChEBI | | Estinyl | Kegg | | 17a-Ethinyl estradiol | Generator | | 17Α-ethinyl estradiol | Generator | | 17-Ethynylestradiol | HMDB | | 17-Ethynylestradiol ram | HMDB | | 17-Ethynyloestradiol | HMDB | | 17a-Ethinyl-17b-estradiol | HMDB | | 17a-Ethinylestradiol | HMDB | | 17a-Ethynyl-17b-oestradiol | HMDB | | 17a-Ethynylestradiol-L7b | HMDB | | 17a-Ethynyloestradiol | HMDB | | 17a-Ethynyloestradiol-17b | HMDB | | Alora | HMDB | | Amenoron | HMDB | | Anovlar | HMDB | | Chee-O-gen | HMDB | | Chee-O-genf | HMDB | | Diognat-e | HMDB | | Diogyn e | HMDB | | Diogyn-e | HMDB | | Dyloform | HMDB | | Ertonyl | HMDB | | Esclim | HMDB | | Esteed | HMDB | | Estigyn | HMDB | | Eston-e | HMDB | | Estoral | HMDB | | Estoral {[orion]} | HMDB | | Estorals | HMDB | | Estring | HMDB | | Estrogen | HMDB | | Ethidol | HMDB | | Ethinoral | HMDB | | Ethinylestriol | HMDB | | Ethynylestradiol | HMDB | | Eticyclin | HMDB | | Eticyclol | HMDB | | Eticylol | HMDB | | Etinestrol | HMDB | | Etinestryl | HMDB | | Etinoestryl | HMDB | | Etistradiol | HMDB | | Etivex | HMDB | | Feminone | HMDB | | Fempatch | HMDB | | Follicoral | HMDB | | Ginestrene | HMDB | | Gynodiol | HMDB | | Gynolett | HMDB | | Inestra | HMDB | | Innofem | HMDB | | Kolpolyn | HMDB | | Linoral | HMDB | | Lynoral | HMDB | | Menolyn | HMDB | | Menostar | HMDB | | Neo-estrone | HMDB | | Nogest-S | HMDB | | Novestrol | HMDB | | Oradiol | HMDB | | Orestralyn | HMDB | | Orestrayln | HMDB | | Ovex | HMDB | | Palonyl | HMDB | | Perovex | HMDB | | Primogyn | HMDB | | Primogyn C | HMDB | | Primogyn m | HMDB | | Progynon C | HMDB | | Progynon m | HMDB | | Spanestrin | HMDB | | Thiuram e | HMDB | | Thiuranide | HMDB | | Vagifem | HMDB | | Ylestrol | HMDB | | Ethinyl estradiol, (8 alpha)-isomer | HMDB | | Ethinyl estradiol, (8 alpha,17 alpha)-isomer | HMDB | | Jenapharm, ethinylestradiol | HMDB | | Effik brand OF ethinyl estradiol | HMDB | | Estradiol, ethynyl | HMDB | | Ethinyl estradiol hemihydrate | HMDB | | Ethinyl estradiol, (9 beta,17 alpha)-isomer | HMDB | | Ethinylestradiol jenapharm | HMDB | | Microfollin | HMDB | | Microfollin forte | HMDB | | Estradiol, ethinyl | HMDB | | Ethinyl estradiol, (8 alpha,9 beta,13 alpha,14 beta)-isomer | HMDB | | Ethinyl oestradiol effik | HMDB | | Schering brand OF ethinyl estradiol | HMDB | | Schering-plough brand OF ethinyl estradiol | HMDB | | Ethinyl-oestradiol effik | HMDB | | Hemihydrate, ethinyl estradiol | HMDB | | Jenapharm brand OF ethinyl estradiol | HMDB | | Organon brand OF ethinyl estradiol | HMDB |
|
|---|
| Chemical Formula | C20H24O2 |
|---|
| Average Molecular Weight | 296.4034 |
|---|
| Monoisotopic Molecular Weight | 296.177630012 |
|---|
| IUPAC Name | (1S,10R,11S,14R,15S)-14-ethynyl-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol |
|---|
| Traditional Name | (1S,10R,11S,14R,15S)-14-ethynyl-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol |
|---|
| CAS Registry Number | 57-63-6 |
|---|
| SMILES | [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3 |
|---|
| InChI Identifier | InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1 |
|---|
| InChI Key | BFPYWIDHMRZLRN-SLHNCBLASA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Estrane steroids |
|---|
| Direct Parent | Estrogens and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Estrogen-skeleton
- 3-hydroxysteroid
- Hydroxysteroid
- 17-hydroxysteroid
- Phenanthrene
- Tetralin
- 1-hydroxy-2-unsubstituted benzenoid
- Benzenoid
- Ynone
- Cyclic alcohol
- Tertiary alcohol
- Acetylide
- Organic oxygen compound
- Organooxygen compound
- Hydrocarbon derivative
- Alcohol
- Aromatic homopolycyclic compound
|
|---|
| Molecular Framework | Aromatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 183 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.011 mg/mL at 27 °C | Not Available | | LogP | 3.67 | HANSCH,C ET AL. (1995) |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.28 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 15.1167 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.28 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2264.9 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 376.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 195.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 187.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 477.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 835.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 740.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 91.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1373.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 492.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1505.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 463.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 425.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 312.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 338.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 26.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 17a-Ethynylestradiol,1TMS,isomer #1 | C#C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(O)=CC=C4[C@H]3CC[C@@]21C | 2763.4 | Semi standard non polar | 33892256 | | 17a-Ethynylestradiol,1TMS,isomer #2 | C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC=C4[C@H]3CC[C@@]21C | 2733.1 | Semi standard non polar | 33892256 | | 17a-Ethynylestradiol,2TMS,isomer #1 | C#C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC=C4[C@H]3CC[C@@]21C | 2844.6 | Semi standard non polar | 33892256 | | 17a-Ethynylestradiol,1TBDMS,isomer #1 | C#C[C@]1(O[Si](C)(C)C(C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(O)=CC=C4[C@H]3CC[C@@]21C | 3032.8 | Semi standard non polar | 33892256 | | 17a-Ethynylestradiol,1TBDMS,isomer #2 | C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC=C4[C@H]3CC[C@@]21C | 3023.6 | Semi standard non polar | 33892256 | | 17a-Ethynylestradiol,2TBDMS,isomer #1 | C#C[C@]1(O[Si](C)(C)C(C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC=C4[C@H]3CC[C@@]21C | 3360.2 | Semi standard non polar | 33892256 |
|
|---|
| General References | - Kaufer D, Ogle WO, Pincus ZS, Clark KL, Nicholas AC, Dinkel KM, Dumas TC, Ferguson D, Lee AL, Winters MA, Sapolsky RM: Restructuring the neuronal stress response with anti-glucocorticoid gene delivery. Nat Neurosci. 2004 Sep;7(9):947-53. Epub 2004 Aug 8. [PubMed:15300253 ]
- Czernik PJ, Little JM, Barone GW, Raufman JP, Radominska-Pandya A: Glucuronidation of estrogens and retinoic acid and expression of UDP-glucuronosyltransferase 2B7 in human intestinal mucosa. Drug Metab Dispos. 2000 Oct;28(10):1210-6. [PubMed:10997942 ]
- Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S, Siegfried JM: Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002 Apr 1;62(7):2141-50. [PubMed:11929836 ]
- Li X, Strauss L, Kaatrasalo A, Mayerhofer A, Huhtaniemi I, Santti R, Makela S, Poutanen M: Transgenic mice expressing p450 aromatase as a model for male infertility associated with chronic inflammation in the testis. Endocrinology. 2006 Mar;147(3):1271-7. Epub 2005 Nov 23. [PubMed:16306085 ]
- Wernert N: [Immunohistochemistry of the prostate and prostate carcinomas]. Veroff Pathol. 1991;135:1-163. [PubMed:2038892 ]
- Zhang L, Sukhareva M, Barker JL, Maric D, Hao Y, Chang YH, Ma W, O'Shaughnessy T, Rubinow DR: Direct binding of estradiol enhances Slack (sequence like a calcium-activated potassium channel) channels' activity. Neuroscience. 2005;131(2):275-82. [PubMed:15708472 ]
- Herrero P, Soto PF, Dence CS, Kisrieva-Ware Z, Delano DA, Peterson LR, Gropler RJ: Impact of hormone replacement on myocardial fatty acid metabolism: potential role of estrogen. J Nucl Cardiol. 2005 Sep-Oct;12(5):574-81. [PubMed:16171718 ]
- Shah MG, Maibach HI: Estrogen and skin. An overview. Am J Clin Dermatol. 2001;2(3):143-50. [PubMed:11705091 ]
- Safi R, Kovacic A, Gaillard S, Murata Y, Simpson ER, McDonnell DP, Clyne CD: Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy. Cancer Res. 2005 Dec 15;65(24):11762-70. [PubMed:16357189 ]
- vom Saal FS, Grant WM, McMullen CW, Laves KS: High fetal estrogen concentrations: correlation with increased adult sexual activity and decreased aggression in male mice. Science. 1983 Jun 17;220(4603):1306-9. [PubMed:6857252 ]
- Schmitt PM, Gohil K, Kaufman MP: Spinal estrogen attenuates the exercise pressor reflex but has little effect on the expression of genes regulating neurotransmitters in the dorsal root ganglia. J Appl Physiol (1985). 2006 Mar;100(3):958-64. Epub 2005 Nov 23. [PubMed:16306253 ]
- Kalaitzidis D, Ok J, Sulak L 2nd, Starczynowski DT, Gilmore TD: Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells. Oncogene. 2004 Sep 30;23(45):7580-7. [PubMed:15326488 ]
- Pierard-Franchimont C, Letawe C, Goffin V, Pierard GE: Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study. Maturitas. 1995 Sep;22(2):151-4. [PubMed:8538484 ]
- de la Monte SM, Moore GW, Hutchins GM: Metastatic behavior of prostate cancer. Cluster analysis of patterns with respect to estrogen treatment. Cancer. 1986 Aug 15;58(4):985-93. [PubMed:3719562 ]
- Harris H, Henderson R, Bhat R, Komm B: Regulation of metallothionein II messenger ribonucleic acid measures exogenous estrogen receptor-beta activity in SAOS-2 and LNCaPLN3 cells. Endocrinology. 2001 Feb;142(2):645-52. [PubMed:11159835 ]
- Frolich A, Christensen L, Andersen J: Estrogen receptors appear undetectable in the C-cells of the human thyroid gland. Bone. 1990;11(6):393-6. [PubMed:1706609 ]
- Siiteri PK: Review of studies on estrogen biosynthesis in the human. Cancer Res. 1982 Aug;42(8 Suppl):3269s-3273s. [PubMed:7083184 ]
- Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA: Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev. 2005 May;26(3):465-78. Epub 2005 Apr 27. [PubMed:15857973 ]
- Moro L, Reineri S, Piranda D, Pietrapiana D, Lova P, Bertoni A, Graziani A, Defilippi P, Canobbio I, Torti M, Sinigaglia F: Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood. 2005 Jan 1;105(1):115-21. Epub 2004 Jun 15. [PubMed:15198955 ]
- Nakano Y, Oshima T, Ozono R, Ueda A, Oue Y, Matsuura H, Sanada M, Ohama K, Chayama K, Kambe M: Estrogen replacement suppresses function of thrombin stimulated platelets by inhibiting Ca(2+) influx and raising cyclic adenosine monophosphate. Cardiovasc Res. 2002 Feb 15;53(3):634-41. [PubMed:11861034 ]
- (). FDA label.. .
|
|---|